Dyadic International, Inc. (DYAI)
NASDAQ: DYAI · Real-Time Price · USD
0.810
-0.010 (-1.21%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Dyadic International Employees
Dyadic International had 6 employees as of December 31, 2024. The number of employees decreased by 1 or -14.29% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-14.29%
Revenue / Employee
$515,058
Profits / Employee
-$1,227,438
Market Cap
29.52M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 123 |
| IGC Pharma | 70 |
| Evaxion | 46 |
| Senti Biosciences | 34 |
| Boundless Bio | 28 |
| Daré Bioscience | 24 |
| Lisata Therapeutics | 21 |
DYAI News
- 4 weeks ago - Dyadic International Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 6 weeks ago - Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices - GlobeNewsWire
- 6 weeks ago - Dyadic International Transcript: Life Sciences Virtual Investor Forum - Transcripts
- 6 weeks ago - Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026 - GlobeNewsWire
- 7 weeks ago - Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free) - GlobeNewsWire
- 2 months ago - Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone - GlobeNewsWire
- 2 months ago - Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin - GlobeNewsWire